TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preparation (Claimed): The preparation of (I) or (II), comprises reacting (XXII) with a compound of metal (M). Preferred Components: The compound (I) or (II) comprises substituted phenyl compound of formula (III), substituted anthracene compounds of formula (IV), (V), (VI), substituted benzo(a)anthracene compounds of formula (VII), (VIII), substituted pyrene compound of formula (IX), substituted 9,9'-spirobi(fluorene) compound of formula (X), substituted 11,11,12,12-tetramethyl-11,12-dihydro-indeno(2,1-a)fluorene compound of formula (XI) or substituted 6,6,12,12-tetramethyl-6,12-dihydro-indeno(1,2-b)fluorene compound of formula (XII).R10 = quinoline complex of formula (Ie), preferably quinoline complex of formula (Ii), (Ij), (Ik) or (Il) or H;R11 = H or heterocyclic moiety of formula (If) or (Ig);V2 = O, S or NR4; andQ1 = N or CR3, where at least one Q1, preferably at least 2 Q1 represents N.Provided that: if R1 is not present, then (Ie) is bonded to (III)-(XII) at this site; and at least one R10 and at least one R11 in all compounds, do not represent H. Preferred Definitions:    M = Li, Al, Zr (preferred), Be, Ca, Mg, Ba, Zn, B, Cu, Sc or Y;    A1 = phenylene, naphthylene, anthracenylene, benzo(a)anthracenylene, pyrenylene, 9,9'-spirobi(fluorenylene), 11,11,12,12-tetramethyl-11,12-dihydro-indeno(2,1-a)fluorenylene or 6,6,12,12-tetramethyl-6,12-dihydro-indeno(1,2-b)fluorenylene (all optionally substituted by at least one group R9);    G = 1-phenyl-1H-benzoimidazolyl, 1H-benzoimidazole-1-yl, 2,4-diphenyl-(1,3,5)triazine-6-yl, 4,6-diphenyl-pyrimidine-2-yl, 2,4-diphenyl-pyrimidine-6-yl, pyrimidinyl, pyridinyl, 1H-(1,2,4)triazolyl, benzothiazolyl, benzooxazolyl, thiazolyl, oxazolyl or 1H-tetrazole-1,5-diyl moiety of formula (Id) (all optionally substituted by at least one substituent R2, R3 or R4);    Y1, Y2 = phenylene, naphthylene, anthracenylene (all optionally substituted by at least one substituent R6) or not present; and    L1 = bidentate ligand, preferably 8-hydroxyquinoline (optionally substituted).    SPECIFIC COMPOUNDS - 160 Compounds (I) are disclosed e.g. lithium-5,5'-(2-(4-(1-phenyl-1H-benzo(d)imidazol-2-yl)phenyl)anthracene-9,10-diyl)bis-8-quinolinolate (Ia), lithium-5-(3-(4-(1-Phenyl-1H-benzoimidazol-2-yl)-phenyl)-anthracen-9-yl)-8-quinolinolate, lithium-5-(2-(4-(1-Phenyl-1H-benzoimidazol-2-yl)-phenyl)-anthracen-9-yl)-8-quinolinolate, lithium-7,7'-(2-(4-(1-phenyl-1H-benzo(d)imidazol-2-yl)phenyl)anthracene-9,10-diyl)bis-8-quinolinolate, lithium-7-(3-(4-(1-Phenyl-1H-benzoimidazol-2-yl)-phenyl)-anthracen-9-yl)-8-quinolinolate.    EXAMPLE - Solution of 8-hydroxyquinoline (25.0 g), sodium iodide (26 g) and sodium hydroxide (6.9 g) in methanol (750 ml) was degassed for 60 minutes at room temperature. After cooling the reaction mixture to -30 degrees C, 5% aqueous sodium hypochlorite solution (250 ml) was added dropwise. Then the mixture was vigorously stirred at -30 degrees C for 30 minutes and then worked up to obtain 8-hydroxy-5-iodoquinoline. Then 8-hydroxy-5-iodoquinoline (7.0 g), imidazole (1.85 g) and tert-butyldimethylsilyl chloride (4.28 g) was dissolved in anhydrous dichloromethane (40 ml) under nitrogen. Then the mixture was stirred vigorously overnight and worked up to obtain 8-(tert-butyldimethylsilyloxy)-5-iodo-quinoline. Then N-phenyl-o-phenylenediamine (50 g) was dissolved in anhydrous N,N-dimethylformamide (400 ml) under nitrogen and 4-bromobenzaldehyde (45.5 g, 0.25 mol) was added to it dropwise. Then the reaction mixture was heated to 40 degrees C and oxone (98.1 g) was added in portions. After stirring for 120 minutes water (1 liter) was added to the reaction mixture at room temperature. Then the reaction mixture was worked up to obtain 2-(4-bromophenyl)-1-phenyl-1H-benzimidazole. Then a mixture of 2-(4-bromophenyl)-1-phenyl-1H-benzimidazole (20.0 g), bis(pinacolato)diboron (16.0 g), potassium acetate (18.6 g), (1,1-bis(diphenylphosphino)ferrocene)dichloropalladium(II) (0.75 g) in dichloromethane and dioxane (360 ml) was degassed for 30 minutes. Then the reaction mixture was heated for 6 hours under reflux. Then the reaction mixture was worked up to obtain 1-phenyl-2-(4-(4,4,5,5-tetramethyl-(1,3,2) dioxaborolan-2-yl)-phenyl)-1H-benzimidazole. Then a mixture of 1-phenyl-2-(4-(4,4,5,5-tetramethyl-(1,3,2) dioxaborolan-2-yl)-phenyl)-1H-benzimidazole (8.9 g), 8-(tert-butyldimethylsilyloxy)-5-iodoquinoline (7.2 g), toluene (110 ml) and dioxane (110 ml) was degassed for 30 minutes by passing nitrogen. Then palladium(II) acetate (9 mg) and tris-o-tolylphosphine (75.6 mg) was added and the mixture was heated for 8 hours at 80 degrees C. Then the reaction mixture was worked up to obtain 8-(tert-butyl-dimethyl-silanyloxy)-5-(4-(1-phenyl-1H-benzimidazol-2-yl)-phenyl)-quinoline. Then 1M tetra-n-butylammonium fluoride solution in tetrahydrofuran (22.4 ml) was added dropwise to a solution of 8-(tert-butyl-dimethyl-silanyloxy)-5-(4-(1-phenyl-1H-benzimidazol-2-yl)-phenyl)-quinoline (7.9 g) in tetrahydrofuran (20 ml). After stirring the mixture for 4 hours, the reaction mixture was worked up to obtain 5-(4-(1-phenyl-1H-benzimidazol-2-yl)-phenyl)-quinolin-8-ol. Then 5-(4-(1-phenyl-1H-benzimidazol-2-yl)-phenyl)-quinolin-8-ol (2.1 g) was dissolved in acetonitrile (100 ml) and 2.5 M n-butyllithium (1.9 ml) was added to it. Then the solution was stirred for 1 hour at room temperature and then worked up to obtain lithium-5-(4-(1-phenyl-1H-benzimidazol-2-yl)-phenyl)-8-hydroxyquinolate.